NASH: Novel therapeutic strategies targeting ASK1 in NASH
Currently, no pharmacological therapies are approved for the treatment of NASH. A new study now identifies CASP8 and FADD-like apoptosis regulator (CFLAR) as a novel suppressor of NASH and its associated disorders in a process dependent on the activation of apoptosis signal-regulating kinase 1 (ASK1).
Refers to Wang, P.-X. et al. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat. Med.http://dx.doi.org/10.1038/nm.4290 (2017)